Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors

Depression and Anxiety

Volumn 19, Issue 2, 2004, Pages 121-126

  Adson, David E ^a,b   Kushner, Matt G ^a   Eiben, Kathryn M ^a   Schulz, S Charles ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anxiety; Clinical trial; Depression; Quetiapine; SSRIs

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; FLUOXETINE; LORAZEPAM; NEUROLEPTIC AGENT; PAROXETINE; PROLACTIN; PSYCHOTROPIC AGENT; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADJUVANT THERAPY; ADULT; ANXIETY; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HABITUATION; HUMAN; MALE; OPEN STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; STATISTICAL ANALYSIS; SYMPTOM; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS;

EID: 1642346811     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.10137     Document Type: Article

References (18)

1. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. Fourth edition. Washington, DC: American Psychiatric Press.
2. Aditjanjee, Schulz SC. 2002. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 63 (Suppl 13): 32-38.
3. Brecher M, Melvin K. 2000. The effect of long-term quetiapine monotherapy on weight in patients with schizophrenia. Presented at the annual meeting of the American College of Neuropsychopharmacology, December 10-14, San Juan, Puerto Rico.
4. Goldstein J. 1999. Quetiapine fumarte (seroquel): A new atypical antipsychotic. Drugs Today 35:193-210.
5. Gorman JM. 2002. Treatment of generalized anxiety disorder. J Clin Psychiatry 2;63 (Suppl 8):17-23.
6. Kapur S, Remington G. 2001. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517.
7. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshelman S, Wittchen HU, Kendler KS. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19.
8. Leo RJ. 1996. Movement disorders associated with the serotonin selective re-uptake inhibitors. J Clin Psychiatry 57:449-454.
9. Maguire GA. 2002. Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences. J Clin Psychiatry 63 (Suppl 4):56-62.
10. Mitchell JE, Maki DD, Adson DE. 1997. The selectivity of inclusion and exclusion criteria in bulimia nervosa treatment studies. Int J Eat Disord 22:243-252.
11. Noyes R Jr. 2001. Comorbidity in generalized anxiety disorder. Psychiatr Clin North Am 24:41-55.
12. Prior TI, Baker GB. 2003. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28:99-112.
13. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. 2001. A novel augmentation strategy for treating resistant major depression Am J Psychiatry 158:131-134.
14. Stahl SM. 2002. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 63:756-757.
15. Strand M, Hetta J, Rosen A, Sorensen S, Malmstrom R, Fabian C, Marits K, Vetterskog K, Liljestrand AG, Hegen C. 1990. A double-blind, controlled trial in primary care patients with generalized anxiety: A comparison between buspirone and oxazepam. J Clin Psychiatry 51 Suppl:40-45.
16. Thase ME. 2001. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry 62:221-224.
17. Thase ME. 2002. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 63:95-103.
18. Tylee A, Gastpar M, Lepine JP, Mendlewicz J. 1999. DEPRES II (Depression Research in European Society II): A patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 14:139-151.